HLS Therapeutics Inc.
HLTRF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $85,648 | $123,891 | $235,138 | $371,404 |
| - Cash | $17,456 | $21,952 | $20,723 | $21,179 |
| + Debt | $66,450 | $87,621 | $97,345 | $97,566 |
| Enterprise Value | $134,642 | $189,560 | $311,760 | $447,791 |
| Revenue | $56,619 | $63,074 | $61,467 | $60,009 |
| % Growth | -10.2% | 2.6% | 2.4% | – |
| Gross Profit | $47,622 | $55,450 | $56,486 | $56,037 |
| % Margin | 84.1% | 87.9% | 91.9% | 93.4% |
| EBITDA | $17,218 | $12,884 | $17,284 | $25,188 |
| % Margin | 30.4% | 20.4% | 28.1% | 42% |
| Net Income | -$19,655 | -$27,531 | -$23,598 | -$13,117 |
| % Margin | -34.7% | -43.6% | -38.4% | -21.9% |
| EPS Diluted | -0.62 | -0.85 | -0.73 | -0.41 |
| % Growth | 27.1% | -16.4% | -78% | – |
| Operating Cash Flow | $8,003 | $15,789 | $16,942 | $16,429 |
| Capital Expenditures | -$14 | -$189 | -$10,148 | -$4,510 |
| Free Cash Flow | $7,988 | $15,600 | $6,794 | $11,919 |